Eli Lilly and Co Stock

Eli Lilly and Co EBIT 2024

Eli Lilly and Co EBIT

14.71 B USD

Ticker

LLY

ISIN

US5324571083

WKN

858560

In 2024, Eli Lilly and Co's EBIT was 14.71 B USD, a 42.44% increase from the 10.33 B USD EBIT recorded in the previous year.

The Eli Lilly and Co EBIT history

YEAREBIT (undefined USD)
2029e-
2028e-
2027e-
2026e-
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-
2015-
2014-
2013-
2012-
2011-
2010-
2009-
2008-
2007-
2006-
2005-
2004-

Eli Lilly and Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Eli Lilly and Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Eli Lilly and Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Eli Lilly and Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Eli Lilly and Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Eli Lilly and Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Eli Lilly and Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Eli Lilly and Co’s growth potential.

Eli Lilly and Co Revenue, EBIT and net profit per share

DateEli Lilly and Co RevenueEli Lilly and Co EBITEli Lilly and Co Net Income
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined
20040 undefined0 undefined0 undefined

Eli Lilly and Co stock margins

The Eli Lilly and Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Eli Lilly and Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Eli Lilly and Co.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Eli Lilly and Co's sales revenue. A higher gross margin percentage indicates that the Eli Lilly and Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Eli Lilly and Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Eli Lilly and Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Eli Lilly and Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Eli Lilly and Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Eli Lilly and Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Eli Lilly and Co Margin History

Eli Lilly and Co Gross marginEli Lilly and Co Profit marginEli Lilly and Co EBIT marginEli Lilly and Co Profit margin
2029e0 %0 %0 %
2028e0 %0 %0 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %
20070 %0 %0 %
20060 %0 %0 %
20050 %0 %0 %
20040 %0 %0 %

Eli Lilly and Co Aktienanalyse

What does Eli Lilly and Co do?

Eli Lilly and Co. is a global biopharmaceutical company headquartered in Indianapolis, Indiana, USA. The company was founded in 1876 by Colonel Eli Lilly with the aim of manufacturing pharmaceutical products of the highest quality. Eli Lilly began his career in the pharmacy industry and opened his own pharmacy in Indianapolis in 1876. He quickly developed his own medications and eventually established Eli Lilly and Company in 1901. Over the years, the company has continued to evolve and expand its business into numerous areas. Eli Lilly is focused on biopharmaceutical research and development and operates in areas such as oncology, diabetes, neurology, and others. The company's main goal is to develop drugs that can change and improve lives. Eli Lilly invests a high percentage of its revenue into research and development every year. The company has several strategic business units, including human pharmaceuticals, animal pharmaceuticals, and oncology research. Eli Lilly is divided into five main divisions: diabetes, oncology, immunology, neurology, and animal health. The diabetes division focuses on manufacturing insulin products and glucose sensors for the treatment of type 1 and type 2 diabetes, as well as blood glucose meters and other diabetes products. The oncology division focuses on researching and developing drugs to treat cancer. The company currently has several compounds in clinical trials, including a new preparation for the treatment of breast cancer. The immunology division focuses on products for the treatment of autoimmune and inflammatory diseases, such as psoriasis. The neurology division focuses on researching and developing drugs to treat diseases of the nervous system, such as Alzheimer's. The animal health division focuses on animal health products, such as drugs for the treatment of infections in livestock and pets. Eli Lilly is primarily known for its insulin products and treatments in the field of oncology. Some of the company's most well-known products include Humalog, Forteo, Alimta, and Cymbalta. The effectiveness and compliance of the products are monitored by a quality and safety system to ensure that patients receive the highest quality medications. In conclusion, Eli Lilly and Co. is a company with a long history and a unique business model. The company specializes in developing high-quality pharmaceutical products and has continued to evolve since its founding. Eli Lilly has become a leader in various areas such as diabetes, oncology, immunology, neurology, and animal health. They are known for their insulin products and treatments in the field of oncology. The company remains committed to expanding its reach and presence globally and continues to develop innovative products that can improve and change people's lives. Eli Lilly and Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Eli Lilly and Co's EBIT

Eli Lilly and Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Eli Lilly and Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Eli Lilly and Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Eli Lilly and Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Eli Lilly and Co stock

How much did Eli Lilly and Co achieve in EBIT for the current year?

In the current year, Eli Lilly and Co has achieved an EBIT of 14.71 B USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Eli Lilly and Co.

How has the EBIT of Eli Lilly and Co developed in recent years?

The EBIT of Eli Lilly and Co has increased by 42.445% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Eli Lilly and Co?

The EBIT of Eli Lilly and Co is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Eli Lilly and Co pay?

Over the past 12 months, Eli Lilly and Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eli Lilly and Co is expected to pay a dividend of 5.73 USD.

What is the dividend yield of Eli Lilly and Co?

The current dividend yield of Eli Lilly and Co is .

When does Eli Lilly and Co pay dividends?

Eli Lilly and Co pays a quarterly dividend. This is distributed in the months of March, June, September, December.

How secure is the dividend of Eli Lilly and Co?

Eli Lilly and Co paid dividends every year for the past 26 years.

What is the dividend of Eli Lilly and Co?

For the upcoming 12 months, dividends amounting to 5.73 USD are expected. This corresponds to a dividend yield of 0.69 %.

In which sector is Eli Lilly and Co located?

Eli Lilly and Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eli Lilly and Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eli Lilly and Co from 12/10/2024 amounting to 1.3 USD, you needed to have the stock in your portfolio before the ex-date on 11/15/2024.

When did Eli Lilly and Co pay the last dividend?

The last dividend was paid out on 12/10/2024.

What was the dividend of Eli Lilly and Co in the year 2023?

In the year 2023, Eli Lilly and Co distributed 3.92 USD as dividends.

In which currency does Eli Lilly and Co pay out the dividend?

The dividends of Eli Lilly and Co are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Eli Lilly and Co stock can be added to a savings plan with the following providers: Trade Republic, Scalable Capital and Consorsbank

Andere Kennzahlen von Eli Lilly and Co

Our stock analysis for Eli Lilly and Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eli Lilly and Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.